Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02825641
Other study ID # 0213-15-RMB
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2016
Est. completion date September 30, 2022

Study information

Verified date October 2022
Source Rambam Health Care Campus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is intended to compare expectant management and on presentation labor induction in women with premature rupture of membranes. The means of labor induction and cervical ripening are either oxytocin or dinoprostone. Expectant management in this obstetrical state means waiting 24 hours from the onset of rupture of membranes and then commencing labor induction with either oxytocin or dinoprostone depending on the patient's obstetrical history and cervical condition. The investigators' hypothesis is that active management will lead to a higher rate of vaginal deliveries, a shorter interval between the time of rupture of membranes and the time of delivery, a lower rate of cesarean sections and a better obstetric result for the mother and the fetus/newborn.


Description:

In the setting of premature rupture of membranes in term pregnancies, it is customary in women who are not in active labor to wait for 24 hours before attempting to induce labor. The means of labor induction used at our medical center are either intravenous oxytocin or per-vaginal dinoprostone, depending on patient's obstetric history and cervical conditions. The investigators hypothesize that commencing induction of labor at presentation in these women by either means of induction will lead to higher rates of vaginal delivery, shorter intervals between the time of onset of rupture of membranes and the time of delivery and lower rates of cesarean sections. The participants in the study, upon signing informed consents, will be randomized to 4 groups-2 groups of expectant management in which labor induction will be commenced after 24 hours with either oxytocin or dinoprostone and 2 groups of active management in which labor induction will be commenced at presentation with either oxytocin or dinoprostone. The participants will be followed from the time of presentation with rupture of membranes at the delivery room and until the time of delivery. Further obstetric, clinical and demographic information will be acquired from the patient's electronic medical file for analysis accuracy and sub-analysis.


Recruitment information / eligibility

Status Completed
Enrollment 458
Est. completion date September 30, 2022
Est. primary completion date November 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Term pregnancies >37 weeks of gestation. - Certain rupture of membranes. - Bishop score < 6. - Singleton pregnancies. - Vertex presentation. - No obstetric or clinical contraindications for labor induction. - Reactive non stress test on presentation. Exclusion Criteria: - Previous cesarean section. - Previous uterine surgeries (Myomectomy etc.). - Placenta Previa. - Multiple gestation pregnancies. - Pregnancies with history of fetal reduction or Intrapartum uterine fetal demise. - Known fetal defects/Chromosomal abnormalities. - Active genital Herpes. - HIV carrier. - Contractions that are less than 10 minutes apart.

Study Design


Related Conditions & MeSH terms

  • Fetal Membranes, Premature Rupture
  • Medical Induction of Labor Affecting Newborn
  • Rupture

Intervention

Drug:
Oxytocin
Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.
Dinoprostone
Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.

Locations

Country Name City State
Israel Rambam health care campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vaginal delivery rate The percentage of participants that achieved vaginal delivery Up to 7 days from the time of presentation with rupture of membranes
Secondary Interval to delivery Interval from the time of onset of premature rupture of membranes and the time of delivery (In minutes) Up to 7 days from the time of presentation with rupture of membranes
Secondary Caesarian delivery rate The percentage of participants that required caesarian delivery Up to 7 days from the time of presentation with rupture of membranes